However, VDR polymorphisms (BsmI and FokI) showed no impact on ninety-day survival rate of acute kidney injury patients [23]. GC, VDR, and RXRA polymorphisms were not associated with risk of death in patients on RRT in our retrospective analysis [2]. CASR polymorphic variants had no impact on all-cause and cardiovascular mortalities in HD patients as well as on the occurrence of cardiovascular events and all-cause mortality in renal transplant recipients in retrospective studies [24, 25]. The gene discussed is CASR; the disease is Huntington disease.